CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Repros Therapeutics Inc.  (RPRX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 
 

RPRX's Revenue Year on Year Growth by Quarter and Year

Repros Therapeutics's Revenue results by quarter and year



Select the Comparisons : Select the Ratio:                        
RPRX Revenue (in millions $) FY 2017 FY 2016 FY 2015 FY 2014
IV Quarter December - 0.01 0.01 -
III Quarter September - 0.01 - -
II Quarter June 0.01 0.02 - -
I Quarter March 0.01 0.02 - -
FY   0.02 0.06 0.01 -

Financial Statements
Repros Therapeutics's second quarter 2017 Revenue $ 0.01 millions RPRX's Income Statement
Repros Therapeutics's second quarter 2016 Revenue $ 0.02 millions Quarterly RPRX's Income Statement
RPRX's Growth by Division See RPRX's Growth by Segment

RPRX Revenue ( Y/Y Growth %) 2017
2016 2015 2014
IV Quarter December - 0 % - -
III Quarter September - - - -
II Quarter June -65 % - - -
I Quarter March -50 % - - -
FY   - 500 % - -



RPRX Revenue Growth Comment
Repros Therapeutics Inc. reported drop in Revenue in the second quarter by -65% to $ 0.01 millions, from the same quarter in 2016.
The fall in the second quarter Repros Therapeutics Inc.'s Revenue compares unfavorably to the Company's average Revenue doubling of 260.59%.

Looking into second quarter results within Biotechnology & Drugs industry 70 other companies have achieved higher Revenue growth. While Repros Therapeutics Inc.' s Revenue meltdown of -65% ranks overall at the positon no. 3220 in the second quarter.



Revenue Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #71
Healthcare Sector #393
Overall #3220
Revenue Y/Y Growth Statistics
High Average Low
1600 % 260.59 % -99.8 %
(Mar 31 2016)   (Dec 31 2013)

You need to upgrade your Flash Player

Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RPRX's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for RPRX's Competitors
Revenue Growth for Repros Therapeutics's Suppliers
Revenue Growth for RPRX's Customers

You may also want to know
RPRX's Annual Growth Rates RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio
RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons



Companies with similar Revenue meltdown for the quarter ending Jun 30 2017 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2017
Fate Therapeutics Inc -0.10 %$ -0.097 millions
Psychemedics Corp -0.17 %$ -0.165 millions
Halyard Health, Inc. -0.20 %$ -0.200 millions
Xtant Medical Holdings, Inc. -0.25 %$ -0.249 millions
Ocular Therapeutix, Inc. -0.68 %$ -0.680 millions
Emergent Biosolutions Inc. -0.70 %$ -0.705 millions
Tenet Healthcare Corp -0.90 %$ -0.900 millions
Genmark Diagnostics, Inc. -1.22 %$ -1.223 millions
Trovagene, Inc. -1.34 %$ -1.343 millions
Mymetics Corp -1.86 %$ -1.858 millions
Vaso Corp -1.98 %$ -1.982 millions
Recro Pharma, Inc. -2.00 %$ -1.997 millions
Inc Research Holdings, Inc. -2.13 %$ -2.130 millions
Quorum Health Corporation -2.16 %$ -2.165 millions
China Biologic Products Holdings, Inc. -2.34 %$ -2.344 millions
Msa Safety Incorporated -2.44 %$ -2.440 millions
Pacific Biosciences Of California, Inc. -3.25 %$ -3.249 millions
T2 Biosystems, Inc. -3.43 %$ -3.434 millions
Therapeuticsmd, Inc. -3.47 %$ -3.470 millions
Harvard Bioscience Inc -3.53 %$ -3.532 millions
Twinlab Consolidated Holdings, Inc. -3.61 %$ -3.614 millions
Acceleron Pharma Inc -4.32 %$ -4.319 millions
Conformis Inc -4.39 %$ -4.391 millions
Endologix Inc -4.74 %$ -4.744 millions
Steris Plc -4.76 %$ -4.764 millions
China Senior Living Industry International Holding -4.88 %$ -4.883 millions
Becton Dickinson & Co -5.10 %$ -5.097 millions
Cancer Genetics, Inc -5.67 %$ -5.671 millions
Brookdale Senior Living Inc. -5.75 %$ -5.748 millions
Cord Blood America, Inc. -5.91 %$ -5.907 millions